Octreotide
A somatostatin analog widely used in endocrine and neuroendocrine medicine, and one of the most important approved peptide drugs missing from many peptide libraries.
Also referenced as: Sandostatin, Sandostatin LAR
This peptide maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Sandostatin, Sandostatin LAR
FDA label signal · 375 trials · 0 PubMed results
What octreotide is
Octreotide is a somatostatin analog used in regulated medicine for multiple endocrine and neuroendocrine indications.
Why it matters
It is one of the foundational approved peptide drugs and helps anchor the library in real peptide pharmacology beyond research-market compounds.
Regulatory context
Octreotide is FDA approved in the United States and exists in both immediate-release and long-acting forms.
Practical reading note
Octreotide is a reminder that some of the most important peptides in medicine are not trendy at all. They are just deeply established.